Aimovig 70 mg and 140 mg solution for injection in pre filled pen
*Company:
Novartis Ireland LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 05 November 2024
File name
Aimovig_PIL clean PF24-098 may 2024.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 27 July 2023
File name
Aimovig_REG SPC_PF23-0128_15.06.2023_clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 27 July 2023
File name
Aimovig_REG SPC_PF23-0128_15.06.2023_clean.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 02 March 2023
File name
Aimovig_REG PIL_PF23-0049_20.02.2023_clean.pdf
Reasons for updating
- New PIL for new product
Updated on 02 March 2023
File name
Aimovig REGSPC PF23-0049 Feb 2023 _Clean.pdf
Reasons for updating
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 02 March 2023
File name
Aimovig REGSPC PF23-0049 Feb 2023 _Clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 21 December 2021
File name
Aimovig_REGSPC PF 21-0324 _Dec 2021_Clean.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 23 June 2021
File name
Aimovig_REG SPC_PF21-0118_06.05.2021_clean.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 September 2020
File name
Aimovig REGSPC PF 20-0014 Clean_August 2020.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 20 February 2020
File name
Aimovig REGSPC PF 19-0192_Clean Feb 2020 medicines.ie.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 18 February 2020
File name
Aimovig 70mg 140mg REGPIL PF19-0192 MT and IE Clean 02.2020 IPHA.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 18 February 2020
File name
Aimovig REGSPC PF 19-0192_Clean Feb 2020.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 18 September 2019
File name
Aimovig clean Leaflet 70mg and 140mg IPHA.pdf
Reasons for updating
- Correction of spelling/typing errors
Updated on 13 September 2019
File name
Aimovig_140mg-ml_70mg_REGSPC PF19-0186_August 2019_Clean updated.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 02 September 2019
File name
Aimovig_Clean_Leaflet 70mg and 140mg R89 August 2019 IPHA.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 02 September 2019
File name
Aimovig_140mg-ml_70mg_REGSPC PF19-0186_August 2019_Clean.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 24 May 2019
File name
Aimovig_140mg-ml_70mg_Soln_In REGPIL_26-Apr-19_English_Clean.pdf
Reasons for updating
- Introduction of new strength
Updated on 09 May 2019
File name
Aimovig_140mg-ml_70mg_Soln_Inj_REGSPC PF 19-0098_April 2019_Clean.pdf
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 04 December 2018
File name
Aimovig 70mg SmPC updated 04.12.2018.pdf
Reasons for updating
- Change to section 3 - Pharmaceutical form
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 05 November 2018
File name
Aimovig 70mg 1018970_R89_p1_LFT_X-4 RA approved 22.08.2018.pdf
Reasons for updating
- New PIL for new product
Updated on 05 November 2018
File name
Aimovig 70mg SmPC.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Novartis Ireland Limited
Address:
Vista Building, Elm Park Business Park, Merrion Road, Dublin 4, IrelandMedical Information E-mail:
medinfo.dublin@novartis.comTelephone:
+353 1 2601255Fax:
+353 1 2601263